• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Transplant in myeloma: individualized approaches needed depending on context, access and biology.

作者信息

Vaquera-Alfaro Héctor A, Gómez-De León Andrés, Desai Nihar, Mehra Nikita, Mohyuddin Ghulam Rehman

机构信息

Hematology Service, University Hospital "Dr. José Eleuterio González" UANL, Monterrey, Nuevo León, México.

Princess Margaret Cancer Centre, Toronto, ON, Canada.

出版信息

Bone Marrow Transplant. 2025 Jan;60(1):3-5. doi: 10.1038/s41409-024-02428-7. Epub 2024 Oct 6.

DOI:10.1038/s41409-024-02428-7
PMID:39370490
Abstract
摘要

相似文献

1
Transplant in myeloma: individualized approaches needed depending on context, access and biology.骨髓瘤移植：需根据具体情况、可及性和生物学特性采取个体化方法。
Bone Marrow Transplant. 2025 Jan;60(1):3-5. doi: 10.1038/s41409-024-02428-7. Epub 2024 Oct 6.
2
Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma.目前诊治初诊高危多发性骨髓瘤患者的方法。
Curr Hematol Malig Rep. 2021 Apr;16(2):148-161. doi: 10.1007/s11899-021-00631-7. Epub 2021 Apr 19.
3
Advances in biology and therapy of multiple myeloma.多发性骨髓瘤的生物学与治疗进展
Hematology Am Soc Hematol Educ Program. 2003:248-78.
4
Short overview on the current standard of treatment in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤当前治疗标准的简要概述。
Memo. 2018;11(1):59-64. doi: 10.1007/s12254-018-0383-3. Epub 2018 Feb 21.
5
Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients.多发性骨髓瘤干细胞移植后十年发生第二原发性恶性肿瘤及死亡的风险增加：对14532例患者的分析
Cureus. 2021 Jul 13;13(7):e16372. doi: 10.7759/cureus.16372. eCollection 2021 Jul.
6
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.多发性骨髓瘤患者在 Myeloma IX 和 Myeloma XI 三期随机对照试验中的血栓形成。
Blood. 2020 Aug 27;136(9):1091-1104. doi: 10.1182/blood.2020005125.
7
Recent advances in understanding multiple myeloma.多发性骨髓瘤认识方面的最新进展。
F1000Res. 2016 Aug 23;5. doi: 10.12688/f1000research.8777.1. eCollection 2016.
8
Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper.不适合移植的新诊断多发性骨髓瘤：当前和未来的临床护理方法：老年肿瘤学青年国际学会评论论文。
J Geriatr Oncol. 2021 May;12(4):499-507. doi: 10.1016/j.jgo.2020.12.001. Epub 2020 Dec 17.
9
Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review.多发性骨髓瘤的基因组和分子改变及其在风险适应性治疗策略中的应用见解：简明临床综述
Int J Genomics. 2017;2017:6934183. doi: 10.1155/2017/6934183. Epub 2017 Nov 8.
10
Current management and emerging treatment strategies for multiple myeloma.多发性骨髓瘤的当前管理及新兴治疗策略
Rinsho Ketsueki. 2019;60(9):1243-1256. doi: 10.11406/rinketsu.60.1243.

本文引用的文献

1
Multiple myeloma in Latin America: A systematic review.拉丁美洲的多发性骨髓瘤：一项系统综述。
EJHaem. 2024 Jun 10;5(4):867-878. doi: 10.1002/jha2.905. eCollection 2024 Aug.
2
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
3
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.多发性骨髓瘤患者不可持续的可测量残留疾病阴性的预测因素。
Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080.
4
Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients.多发性骨髓瘤患者自体造血细胞移植后感染并发症的特征和结果。
Transpl Infect Dis. 2023 Oct;25(5):e14123. doi: 10.1111/tid.14123. Epub 2023 Aug 12.
5
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.三药联合治疗、移植和维持治疗直至骨髓瘤进展。
N Engl J Med. 2022 Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5.
6
Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials.自体移植对伴有高危细胞遗传学的初诊多发性骨髓瘤患者生存的影响：一项随机对照试验的荟萃分析。
Cancer. 2022 Jun 15;128(12):2288-2297. doi: 10.1002/cncr.34211. Epub 2022 Apr 4.
7
Diagnosis and Management of Multiple Myeloma: A Review.多发性骨髓瘤的诊断与治疗：综述
JAMA. 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003.
8
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.在新诊断的多发性骨髓瘤患者中，硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗和自体干细胞移植治疗后，用达雷妥尤单抗或观察进行维持治疗（CASSIOPEIA）：一项开放标签、随机、3 期试验。
Lancet Oncol. 2021 Oct;22(10):1378-1390. doi: 10.1016/S1470-2045(21)00428-9. Epub 2021 Sep 13.
9
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
10
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.硼替佐米、来那度胺和地塞米松诱导治疗及适应性维持治疗新诊断多发性骨髓瘤的长期随访结果。
J Clin Oncol. 2020 Jun 10;38(17):1928-1937. doi: 10.1200/JCO.19.02515. Epub 2020 Apr 16.